Denali Therapeutics (DNLI) Competitors $14.95 +0.08 (+0.53%) As of 09:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DNLI vs. BEAM, BPMC, ROIV, ELAN, RGC, LEGN, RVMD, GRFS, TGTX, and NUVLShould you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Beam Therapeutics (BEAM), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Regencell Bioscience (RGC), Legend Biotech (LEGN), Revolution Medicines (RVMD), Grifols (GRFS), TG Therapeutics (TGTX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Denali Therapeutics vs. Its Competitors Beam Therapeutics Blueprint Medicines Roivant Sciences Elanco Animal Health Regencell Bioscience Legend Biotech Revolution Medicines Grifols TG Therapeutics Nuvalent Denali Therapeutics (NASDAQ:DNLI) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability. Does the media refer more to DNLI or BEAM? In the previous week, Beam Therapeutics had 1 more articles in the media than Denali Therapeutics. MarketBeat recorded 8 mentions for Beam Therapeutics and 7 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.11 beat Beam Therapeutics' score of 0.55 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is DNLI or BEAM more profitable? Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -609.24%. Denali Therapeutics' return on equity of -35.90% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Denali TherapeuticsN/A -35.90% -32.41% Beam Therapeutics -609.24%-44.24%-30.97% Which has stronger earnings & valuation, DNLI or BEAM? Beam Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDenali Therapeutics$330.53M6.57-$422.77M-$2.67-5.60Beam Therapeutics$63.52M32.61-$376.74M-$4.61-4.47 Which has more risk & volatility, DNLI or BEAM? Denali Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Do analysts prefer DNLI or BEAM? Denali Therapeutics currently has a consensus target price of $33.71, suggesting a potential upside of 125.53%. Beam Therapeutics has a consensus target price of $48.75, suggesting a potential upside of 136.67%. Given Beam Therapeutics' higher probable upside, analysts plainly believe Beam Therapeutics is more favorable than Denali Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 2 Strong Buy rating(s) 3.06Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 3.00 Do institutionals and insiders have more ownership in DNLI or BEAM? 92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by insiders. Comparatively, 3.5% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryDenali Therapeutics and Beam Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNLI vs. The Competition Export to ExcelMetricDenali TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.17B$2.91B$5.51B$9.31BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-5.6120.3628.1819.72Price / Sales6.57290.30439.19110.06Price / CashN/A42.3835.5357.53Price / Book1.757.768.235.67Net Income-$422.77M-$55.11M$3.23B$257.51M7 Day Performance-2.61%0.19%-0.61%-0.16%1 Month Performance6.70%10.80%6.63%9.89%1 Year Performance-35.03%-0.68%27.07%15.08% Denali Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNLIDenali Therapeutics4.6842 of 5 stars$14.95+0.5%$33.71+125.5%-37.9%$2.17B$330.53M-5.61430Positive NewsBEAMBeam Therapeutics2.2387 of 5 stars$21.17+0.0%$48.75+130.3%-26.5%$2.13B$63.52M-4.59510BPMCBlueprint Medicines1.1255 of 5 stars$129.36+0.0%$128.25-0.9%+7.3%$8.35B$508.82M-52.37640Positive NewsHigh Trading VolumeROIVRoivant Sciences2.6311 of 5 stars$11.63+2.4%$16.50+41.9%-0.6%$7.91B$29.05M-46.52860Positive NewsELANElanco Animal Health1.5096 of 5 stars$14.88-0.2%$15.33+3.1%+9.5%$7.39B$4.44B20.109,000Analyst UpgradeRGCRegencell Bioscience0.3405 of 5 stars$14.68-0.5%N/AN/A$7.29BN/A0.0010Positive NewsGap UpLEGNLegend Biotech3.6373 of 5 stars$39.44+1.2%$72.70+84.3%-28.9%$7.25B$627.24M-66.852,609Positive NewsGap UpRVMDRevolution Medicines4.5366 of 5 stars$38.37+0.9%$68.00+77.2%-17.9%$7.15B$11.58M-9.59250Analyst ForecastGRFSGrifols3.5302 of 5 stars$9.72-0.2%$10.30+6.0%+23.8%$6.68B$7.81B8.3123,822Gap UpTGTXTG Therapeutics3.5146 of 5 stars$38.92+5.0%$43.80+12.5%+72.5%$6.18B$329M162.17290NUVLNuvalent3.3271 of 5 stars$84.59+4.5%$119.60+41.4%+1.7%$6.07BN/A-19.2740 Related Companies and Tools Related Companies Beam Therapeutics Competitors Blueprint Medicines Competitors Roivant Sciences Competitors Elanco Animal Health Competitors Regencell Bioscience Competitors Legend Biotech Competitors Revolution Medicines Competitors Grifols Competitors TG Therapeutics Competitors Nuvalent Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNLI) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNLI Stock Alerts